

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVEREST MEDICINES**

**云 頂 新 耀**

**Everest Medicines Limited**

**雲 頂 新 耀 有 限 公 司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1952)**

**VOLUNTARY ANNOUNCEMENT  
BUSINESS UPDATE ON APPROVAL OF  
CLINICAL TRIAL APPLICATION BY CHINA NMPA  
FOR PHASE 3 TRIAL OF XERAVA™  
FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Center for Drug Evaluation of the National Medical Products Administration (“**NMPA**”) of the People’s Republic of China has approved a Clinical Trial Application (“**CTA**”) for Xerava™ (eravacycline) for the treatment of community-acquired bacterial pneumonia (“**CABP**”). With this CTA, the Company plans to conduct a Phase 3 trial in China evaluating the efficacy and safety of eravacycline in treating adult patients with CABP.

Eravacycline is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class. It is currently approved for the treatment of complicated intra-abdominal infections (“**cIAI**”) in the United States (“**US**”) and Europe (“**EU**”), and it was approved for the treatment of cIAI in adults in Singapore in April 2020 and is currently under regulatory review for cIAI in China.

Under a licensing agreement with Tetrphase Pharmaceuticals (now a wholly owned subsidiary of La Jolla Pharmaceutical Company), the Company has exclusive rights to develop and commercialize Xerava™ in Greater China, South Korea, and the key markets of South East Asia, including Indonesia, Malaysia, Philippines, Thailand, Singapore and Vietnam.

## **INFORMATION ABOUT COMMUNITY ACQUIRED BACTERIAL PNEUMONIA**

CABP is defined as an acute bacterial infection of the pulmonary parenchyma associated with chest pain, cough, sputum production, difficulty breathing, chills, rigors, fever, or hypotension and is accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph. Common typical bacterial pathogens that cause CABP include *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, and *Moraxella catarrhalis* as well as Atypical bacterial pathogens such as *Chlamydophila pneumoniae*, *Mycoplasma pneumoniae*, and *Legionella pneumophila*. In 2019, there were as many as 28.1 million cases of CABP in China. The mortality rate and drug resistance rate have shown high correlation with increasing age of the patients. The unmet medical needs are expected to continue to rise with aging population globally.

## **INFORMATION ABOUT XERAVA™ (ERAVACYCLINE)**

Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and are prevalent in China. Xerava™ is currently approved for the treatment of cIAI in the US and EU. The Company received approval of Xerava™ in Singapore for cIAI in April 2020 and the medicine is currently under review for cIAI in China. The Company is also developing Xerava™ for the treatment of CABP. Xerava™ was licensed from Tetrphase Pharmaceuticals, now a wholly owned subsidiary of La Jolla Pharmaceutical Company.

**Cautionary statement:** We cannot guarantee that we will be able to develop, or ultimately market, Xerava™ (eravacycline) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
*Chairman and Executive Director*

Hong Kong, 5 August 2021

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*